3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
21
Active not recruiting
17
Completed
14
Not yet recruiting
9
Terminated
2
Suspended
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Endocrine
1
Conditions
Spinocerebellar Degenerations
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
117
Carboplatin
47
Nivolumab
46
Paclitaxel
34
Cyclophosphamide
34
Cisplatin
33
Gemcitabine
30
atezolizumab
27
Specimen Handling
26
Magnetic Resonance Spectroscopy
25
venetoclax
24
Docetaxel
24
fludarabine
23
Pemetrexed
23
Biopsy
22
Bevacizumab
22
Radiotherapy
21
Ipilimumab
21
Azacitidine
20
Dexamethasone
19
Radiosurgery
18
durvalumab
17
Fluorouracil
17
Cetuximab
16
Trastuzumab
15
fludarabine phosphate
14
Leucovorin
14
Cytarabine
14
tislelizumab
13
Lenalidomide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
trifluridine tipiracil drug combination
×
1 year
×
Clear all
NCT04042714
2025-11-04
TAS-102 NEC
Baylor Research Institute
Phase 2
Terminated
14 enrolled
NCT05328908
2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3
Terminated
770 enrolled